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Abstract
Background—Rotavirus gastroenteritis is a major cause of mortality among children <2 years of 
age. Disease burden data are important for introducing and sustaining new rotavirus vaccines in 
immunization programs.
Methods—We analyzed population-based infectious disease surveillance data from 2007 to 2010 
from Kenyan sites in rural and urban slum areas. Stool specimens were collected from patients of 
all ages presenting to study clinics with diarrheal disease and tested for rotavirus by enzyme 
immunoassay. Incidence rates were adjusted using data on healthcare utilization (from biweekly 
home visits) and proportion of stools collected at study clinics from patients meeting case 
definitions.
Results—Rotavirus was detected in 285 (9.0%) of 3174 stools tested, including 122 (11.9%) 
from children <5 years of age and 162 (7.6%) from participants ≥5 years of age. Adjusted 
incidence rates for infants were 13,419 and 12,135 per 100,000 person-years of observation in 
rural and urban areas, respectively. Adjusted incidence rates were high in adults across age ranges. 
The rates suggest that annually, among children <5 years of age, there are >54,500 cases of 
rotavirus-associated gastroenteritis in rural Nyanza Province and >16,750 cases in Nairobi urban 
slums.
Conclusions—Community-based surveillance in urban and rural Kenya suggests that rotavirus 
plays an important role as a cause of acute gastroenteritis in adults, as well as in children. In 
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addition to substantially preventing illness and complications from diarrheal disease in children, 
rotavirus infant immunization has the potential of indirectly preventing diarrheal disease in older 
children and adults, assuming children are the predominant sources of transmission.
Keywords
rotavirus; gastroenteritis; diarrhea; population-based incidence; rates; children; adults; Kenya; 
urban; rural; vaccine; impact
Interest in precise data on burden of rotavirus gastroenteritis has grown due to the recent 
availability of safe and efficacious new generation rotavirus vaccines.1,2 In addition to direct 
protection, data from high and middle income countries that have introduced rotavirus 
vaccines suggest that immunization of infants may provide indirect protection by reducing 
transmission of rotavirus to older children and adults.3,4 While data are available on 
rotavirus disease burden in children <5 years of age from multiple settings,5 most of these 
data are hospital-based, which does not provide a representative and accurate disease 
incidence data burden in areas where health care utilization is low. In addition, there is 
limited information on incidence rates for rotavirus-associated diarrhea in older children and 
in adults, particularly in developing countries.6,7
The Kenya Medical Research Institute (KEMRI) and the US Centers for Disease Control 
and Prevention (CDC) collaborate on population-based surveillance for infectious disease 
syndromes and their etiologies in a rural setting and in an urban slum in Kenya; adults in 
both areas have high (15–20%) HIV seroprevalence.8 The surveillance platform has 
provided opportunities to assess the burden of a variety of syndromes. We assessed 
incidence and characterized the epidemiology of rotavirus-associated gastroenteritis by age 
group in these 2 locations. These data may serve as a baseline to monitor impact of 
introduction (anticipated in 2014) of rotavirus vaccines, including in older children and 
adults.
METHODS
Study Sites
KEMRI and CDC have collaborated on population-based infectious disease surveillance 
(PBIDS) since late 2005 in 2 sites in Kenya: Lwak (within Rarieda District in Siaya 
County), a rural location in Nyanza province in Western Kenya (Fig. 1), and an urban 
setting in Kibera, a slum in Nairobi.9
Surveillance Procedures
The Kenya PBIDS system for diarrheal disease, febrile illness, pneumonia and jaundice 
surveillance has been described elsewhere [9]. Briefly, trained community interviewers 
visited participants every 2 weeks, collecting data on illnesses and deaths during the 2 weeks 
before visit; after September 1, 2009, household visits were increased in frequency to every 
week to allow for more intensive data collection during the pandemic of influenza A 
H1N1.10 Surveillance participants have free access to a well-staffed and supplied field clinic 
centrally located within 5 km and 1 km of all residences in Lwak and Kibera, respectively.
Breiman et al. Page 2
Pediatr Infect Dis J. Author manuscript; available in PMC 2015 December 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
PBIDS is carried out within 2 of 12 villages in Kibera: Gatwikera and Soweto West. The 
average population of the surveillance area is 28,500 in a 0.37 km2 area (population density 
= 77,000 persons/km2). Kibera lacks adequate sanitation facilities; human and animal wastes 
drain into open sewage runoff. The Lwak surveillance area is 100 km2 with average 
population of 25,000 (325 people/km2), and the area is holoendemic for malaria. The 2 areas 
are 340 km (6–8 travel hours) apart by road. Kibera is at approximately 1600 m altitude and 
the elevation of Lwak is 1000 m. Surveillance participants included all people living in 
consenting households within the surveillance areas for a minimum of 4 months (8 
consecutive biweekly home visits) between January 1, 2007, and December 31, 2010 (the 
study period).
For acute diarrheal disease surveillance, we collected stool specimens from consenting 
patients presenting to the study clinics during the study period. We sampled patients 
presenting with diarrhea, defined as ≥3 loose stools within a 24-hour period. To minimize 
burden on the laboratory, we sampled no more than 5 children and 5 adults a day (from each 
site) who had diarrhea without any sign of dehydration or dysentery. However, there were 
no restrictions on the number of patients sampled who presented with diarrhea and had signs 
of dehydration (defined as having ≥1 of the following signs and symptoms: drinking eagerly 
or unable to drink or breast-feed, vomits everything, slow skin pinch return ≥2 seconds, 
irritability, sunken eyes, lethargy or unconsciousness) or had evidence of dysentery (defined 
as reported or visible blood in at least 1 stool during the 24 hours before clinic visit).
A case of rotavirus gastroenteritis was defined as a patient with a diarrheal illness who had 
rotavirus detected in a stool specimen. To assess the proportion of pathogens detected from 
patients with diarrhea which was likely associated with illness, we also collected stool 
specimens from “control” residents of the surveillance area presenting to the clinic without 
fever, respiratory symptoms or diarrhea during the past 2 weeks, as previously 
described.11,12 Each month, we attempted to enroll a target number of controls for a variety 
of age groups based on a frequency distribution of ages of patients who presented to the 
clinics with respiratory or diarrheal disease and for adults, HIV status. We compared 
proportions of cases and noncases by age group who had rotavirus detected in stool. Odds 
ratios (OR) and 95% confidence intervals (CIs) were calculated using unconditional logistic 
regression, adjusting for age group. We used the OR to calculate pathogen-attributable 
fractions (PAF), which estimate the proportion of cases positive for rotavirus in which it is 
the likely cause of illness.11–13 PAF were calculated as (OR-1)/OR.
Diagnostics
We provided consenting participants meeting the stool collection criteria with a labeled stool 
container and instructions on how to sample their stool. Stool specimens were collected 
from patients’ homes within 4 hours of clinic visit, if they were unable to produce stool at 
the clinic. A sample of whole stool underwent routine enteric microbiology testing14; in 
addition, portions were aliquoted into 2 vials, 1 for rotavirus testing and the other was 
archived. In Kibera, stool specimens were kept at −20°C at the field laboratory and were 
transported daily to the KEMRI/CDC Nairobi laboratory, where they were stored at −80°C 
until testing. Specimens were batch shipped to the KEMRI/CDC Enterics laboratory in 
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Kisumu, Kenya in a dry shipper (at −80°C) for rotavirus testing. Specimens collected in 
Lwak were transferred to the KEMRI/CDC Kisumu laboratory on a daily basis with cool 
packs and stored at −80°C until testing.
At the KEMRI/CDC Enterics laboratory in Kisumu, specimen identification numbers were 
entered into a log book and into a computerized database, and specimens were stored at 2–
8°C. Specimens were batch tested weekly using a commercially available enzyme 
immunoassay kit (Rotaclone, Meridian Premier, Charlotte, NC) for detection of rotavirus 
antigen in the human fecal specimens, as previously described.15
Analysis
Data were analyzed using SAS, version 9.1 (Cary, NC). We calculated crude incidence rates 
as the number of rotavirus gastroenteritis cases among PBIDS participants per 100,000 
participant person-years of observation (PYO). PYO were calculated by totaling person-days 
for all people who met the residence requirement during each biweekly round and dividing 
the total number of person-days by 365.25. A participant who moved away from the 
surveillance area for 4 consecutive months was not counted in the denominator (for 
calculation of PYO) during or after those 4 months. If that person moved back into the 
surveillance area, he/she would not be counted in denominator (or numerator) until 
documented to be living in the surveillance area for 4 months and reconsented to participate 
in the study.
We used 2 incidence rate adjustments to account for the possibility of cases missed due to 
gaps in case detection and diagnosis, as previously described.16 The first (adjustment 1) was 
based on patients who visited the clinic and did not have a stool specimen collection done 
despite meeting the criteria for stool collection. The usual reason given for not having a 
stool specimen obtained was that the patient was not able or willing to produce a stool 
specimen at the clinic or during the required time after clinic visit (see above). For this 
extrapolation, we divided the number of participants meeting stool-sampling criteria who 
had a stool specimen obtained by the total number of all surveillance participants presenting 
to the clinic meeting stool specimen collection criteria. The resulting proportion was divided 
into the crude incidence rate to account for those meeting stool specimen collection criteria 
who were not cultured.
A second adjustment (adjustment 2) was based on dividing the number of patients who had a 
diarrheal illness (based on data from the home visits) and who visited the study clinic by the 
total number of patients who had diarrheal illness and visited any clinic (including nonstudy 
clinics where information and specimens are not collected for this surveillance)—thus, the 
denominator would include patients who felt they were sick enough to visit a clinic but did 
not have the opportunity for stool specimen collection. This figure was divided into 
adjustment 1 to yield adjustment 2. This adjusted rate was then multiplied by the PAF (see 
above) to achieve the final adjusted rate.
Because of the likelihood that healthcare-seeking and stool-sampling patterns vary by type 
of diarrheal syndrome, adjustments 1 and 2 and PAF correction were initially done 
separately for diarrhea without dehydration, diarrhea with evidence of dehydration and 
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dysentery (blood in stool). The adjusted rates for each diarrheal syndrome by age group 
were then summed to provide the final adjusted rates for rotavirus diarrhea by age group for 
Kibera and Lwak. CIs for the crude incidence rates were calculated using the Exact 
method.17 CIs for the final adjusted incidence rates were calculated using the same 
adjustments; that is, the lower and upper ends of the exact CIs were divided by adjustment 1 
and then by adjustment 2, and then those figures were multiplied by the PAF.
We used incidence rates from this study to estimate the annual number of cases of rotavirus 
gastroenteritis occurring among people within the same age groups based on 2009 census 
data in rural Nyanza Province and in urban Nairobi.18 This project was approved by the 
Ethical Review Committee of KEMRI (Protocol #932 and #1899) and Institutional Review 
Board of CDC (Protocol #4566).
RESULTS
We enrolled 48,337 and 35,063 persons in Kibera and Lwak in the study between 2007 and 
2010, who contributed 110,592 and 102,217 PYO, respectively. The overall crude incidence 
rate of rotavirus gastroenteritis was 153/100,000 PYO (Kibera) and 113/100,000 PYO 
(Lwak). In Lwak, crude incidence was highest among children <12 months of age 
(671/100,000 PYO); in Kibera, toddlers, 12–23 months of age, had the highest rate 
(504/100,000 PYO; Table 1 and Table 2). In Kibera, rotavirus was detected in 170 (7.8%) of 
2166 stools from patients with diarrhea compared with 6 (2.1%) of 289 control-patients 
(PAF = 0.75). In Lwak, rotavirus was detected in 115 (11.4%) of 1008 stools collected from 
patients with diarrhea, compared with 9 (1%) of 737 control-patients (PAF = 0.9). Thus, 
rural Lwak residents had an increased likelihood that an episode of acute gastroenteritis was 
associated with detection of rotavirus in stool when compared with urban Kibera residents 
(relative risk = 1.46; 95% CI = 1.16–1.83) and given differences in PAF, a greater likelihood 
that rotavirus was the cause of the episode of gastroenteritis. The difference in rate of 
detection of rotavirus in stools from control residents of Kibera when compared with control 
residents in Lwak was not statistically significant. Mild diarrhea accounted for many 
incidences in both sites; however, in Lwak, a greater proportion of rotavirus gastroenteritis 
was associated with dehydration than in Kibera for all age groups, especially so for children 
<24 months of age (Table 3 and Table 4).
The overall adjusted incidence rates were 1157/100,000 PYO and 1427/100,000 PYO in 
Kibera and Lwak, respectively, with highest rates in children 12–23 months of age followed 
by infants (<12 months of age; Table 3 and Table 4). Rotavirus gastroenteritis incidence 
rates were >220/100,000 PYO for each age group ≥5 years of age with the highest rate 
(437/100,000 PYO) in Kibera in persons 35–49 years of age, which was about one-sixth of 
the rate calculated for children 24–59 months of age (Table 3). In Lwak, the highest rates in 
adults were in the 18–34 year age group (982/100,000 PYO), which was more than half of 
the rate calculated for 24–59 month olds (Table 4).
HIV test results were available from a limited number of patients. In Kibera, among 39 
rotavirus cases ≥18 years old tested for HIV antibodies, 9 (23.1%) were HIV-infected, 
compared with 133 (23.9%) of 557 nonrotavirus-associated diarrhea cases tested for HIV 
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infection. In Lwak, among 29 rotavirus cases ≥18 years old, tested for HIV antibodies, 10 
(34.5%) were HIV-infected compared with 154 (50.2%) of 307 nonrotavirus-associated 
diarrhea cases tested for HIV infection (relative risk = 0.55; 95% CI = 0.26–1.15).
Annual crude rotavirus rates varied across the 4 years of observation from 45 to 195/100,000 
PYO in Kibera and from 85 to 160/100,000 PYO in Lwak. Throughout the 4-year period, 
rotavirus gastroenteritis occurred year round without consistent, specific high incidence 
peaks, although in Kibera, peaks occurred during the cool, dry months of July and August 
for 3 of the 4 years (Fig. 2).
DISCUSSION
This study provides community population-based incidence data for rotavirus gastroenteritis 
in children and adults as a result of rigorously defined denominators and active surveillance 
to identify cases and to adjust incidence based on the proportion of cases likely missed. The 
incidence rates can be used to estimate absolute numbers of cases for people living in similar 
settings, using population census data. While demonstration of high rates in children is not 
unexpected, the study also showed that rotavirus is an important cause of gastroenteritis in 
adults in these settings in Kenya.
Rotavirus crude incidence rates varied substantially annually over the 4-year course of this 
study. This confirms earlier reports of annual incidence variation19 and highlights the 
importance of multiple years of surveillance (and use of alternative approaches, like case-
control studies, cluster designed interventions and severity-impact investigations) to assess 
and document impact of rotavirus vaccine postintroduction. For example, if rotavirus 
vaccine had been introduced in 2007, it would have been tempting to ascribe the 53% 
reduction in incidence (based on surveillance data from a national surveillance system) in 
Lwak when comparing 2008 data with 2007 data, as evidence of vaccine impact; conversely, 
in Kibera, the crude rate increased 4-fold from 2008 to 2009; if vaccine introduction had 
occurred in 2008, there might have been premature and incorrect conclusions of 
ineffectiveness (or increased associated risk) of the immunization program, potentially 
negatively impacting continued enthusiasm.
Rotavirus is often described as an “egalitarian” virus, infecting people regardless of their 
location or socioeconomic status,20 although severity and fatal outcome are dictated by 
comorbidities and access to health care (including oral rehydration solutions).5,19 Despite 
vastly different ecologies found in the sparsely populated rural western Kenya and densely 
populated urban Nairobi, interestingly, the overall rates of rotavirus disease in the 2 areas 
are quite similar. The higher incidence we observed of dehydration-associated rotavirus 
gastroenteritis in the rural area might reflect differential access to rehydration in the 2 areas.
A value of population-based incidence rates is that one can estimate numbers of people 
affected by a disease and project the number of illness episodes that can be prevented by 
applying interventions of known effectiveness. For instance, the 2009 census showed that 
there were 5.4 million people living in Nyanza Province (where the rural Lwak surveillance 
site is located), including 810,000 children <5 years of age. Given an adjusted annual 
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incidence rate of rotavirus gastroenteritis in Lwak of 6779 cases per 100,000 children <5 
years of age, we estimate that there are >54,500 cases per year in children in the Province 
(which represents 13.5% of the national population). If we assume the efficacy of rotavirus 
immunization in this setting to be approximately 60%2 and an 80% vaccine coverage rate, 
then about 26,000 cases would be preventable per year in Nyanza Province alone. Likewise, 
there is an estimated 1.9 million people living in urban slums in Nairobi with an estimated 
285,000 children <5 years of age. The adjusted incidence rate in Kibera for children <5 
years of age of 5887 cases per 100,000 population per year, translates to >16,750 cases per 
year. Using the same vaccine efficacy and estimated coverage rates as above, >8000 cases of 
rotavirus gastroenteritis could be prevented per year in <5 years of age in Nairobi urban 
slums.
Based on data from a variety of studies and sites, it would be possible to estimate 
preventable burden from the estimated proportion of rotavirus gastroenteritis that requires 
hospitalization and the proportion of rotavirus gastroenteritis associated with mortality. Our 
study was not designed to assess mortality from rotavirus or to calculate economic impact 
contributing to disease burden calculations. Given that rotavirus-associated mortality is 
associated with poor or delayed access to rehydration options and that provision of good 
quality health care is a component of participation in the PBIDS from which the incidence 
rates are calculated, we did not expect to observe many deaths. However, most children in 
Kenya do not have this level of access to health care, so the rates of rotavirus illness 
determined during this study could be used to estimate mortality, as has been done during 
global estimates of rotavirus-associated burden.5,19,20 Having estimates of overall burden 
provide a tangible way for policy-makers to assess likely impact of interventions, and for 
donors and vaccine developers to consider potential impact of more effective vaccine 
regimens.
HIV has been known to increase the incidence, shedding and severity of infections due to a 
variety of pathogens21–23 and studies have suggested that HIV-infected adults have an 
increased risk for rotavirus gastroenteritis.24,25 While surprisingly high rates of rotavirus-
associated diarrhea were shown in our study, rotavirus-infected adults were not more likely 
to be infected with HIV than adults with diarrhea due to other causes; thus, it did not appear 
that HIV infection was a specific risk factor for rotavirus infection. Nonetheless, the HIV-
infection rates for adults with diarrhea (with or without rotavirus as an etiology) were higher 
than the seroprevalences of HIV infection in both areas, consistent with evidence that HIV 
infection is associated with greater risk of illness from a variety of gastrointestinal 
pathogens.
More data are needed to assess the impact (including severity and outcome) of rotavirus 
gastroenteritis in adults, especially in areas with high HIV seroprevalence. Vaccinating 
children will be key in directly reducing childhood associated morbidity and death, and there 
may be an indirect benefit of reducing infections in older children and adults.25
While this study was unique in terms of its community-based methods identifying rotavirus 
gastroenteritis in the urban and rural communities we surveyed, and for providing reliable 
basis for rate adjustments, limitations may have led to underestimates or overestimates of 
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the burden of disease. Because of transport requirements to the Kisumu laboratory, stool 
specimens were often processed >24 hours after collection. In calculating adjusted incidence 
rates, we assumed that persons with diarrhea who reported visiting any clinic had similar 
rotavirus gastroenteritis incidence rates as those seen in the study field clinic. We also 
assumed that severity of illness for patients with diarrhea (and the 3 categories of 
dehydration, dysentery and mild diarrhea) who provided stool for testing were not different 
from those of patients who were not sampled. These assumptions would be erroneous if 
there was a systematic bias with regard to whether persons with moderate to severe diarrhea 
went to the designated field clinic and whether patients and clinicians were more aggressive 
about sampling, based on the type or severity of diarrhea. It also should be noted that 
freezing and batch testing of specimens may have reduced sensitivity of the assay.
The findings of this study provide evidence for high community-based incidence of 
rotavirus gastroenteritis, as well as an important role of rotavirus as a cause of diarrheal 
disease in adults, providing the basis for evaluating indirect protection in older children and 
adults when rotavirus immunization programs are implemented. High incidence rates are 
shown in both rural and urban slum settings, supporting expectations for substantial impact 
of universal rotavirus immunization of infants and toddlers in Kenya, and likely elsewhere 
in Africa. In addition, year to year variation of rotavirus-associated diarrhea incidence 
highlights that evaluation of impact of rotavirus immunization will require multiple years of 
observation.
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FIGURE 1. 
Map of Kenya with insets showing location of study sites.
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FIGURE 2. 
Adjusted annual incidence of rotavirus gastroenteritis by month: A) Kibera (2007–2010) and 
B) Lwak (2007–2010). *Actual value of this off-scale data point (December 2008) is 
8000/100,000 person years of observation.
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